Research

NewAmsterdam Pharma will share four BROADWAY-derived analyses at AAIC 2026, including biomarker data suggesting obicetrapib may slow Alzheimer's pathology.

SHARP's Karada Mate Watch integrates HEALBE's bioimpedance-based FLOW platform to estimate calorie intake and hydration automatically.

A three-layer sensor developed at Vilnius University can detect, identify and locate radiation sources in real time, from lab doses to megagray nuclear emergency

The deal separates Beacon from the Hanson Wade Group, giving the R&D intelligence platform independent status backed by Corten's €680m second fund.

Phase 1/2 data presented at ESMO GI show response rates above 60% for zoldonrasib combinations, supporting two planned Phase 3 trials in pancreatic cancer.

A pooled analysis of 8,478 patients shows Myriad's Prolaris Biopsy Test adds prognostic value beyond standard clinical risk tools in localised prostate cancer.

UCLA researchers used Vibrant's ingestible vibrating capsule to study gut-brain signalling as a predictor of relapse risk in anorexia nervosa recovery.

The Marseille biotech will use its VECTrans platform to ferry Servier's oligonucleotides across the blood-brain barrier for rare neurological disorders.

Real-world data from 67,594 US patients shows biosimilar adoption peaked after formulary changes, but switch-back rates highlight gaps in patient support.

Seer has defended a key European proteomics patent and launched a US trade investigation targeting Nanomics' competing Proteonano products.

New York Valves 2026 featured two late-breaking Trilogy datasets, including early outcomes in LVAD patients with aortic regurgitation showing 7.3% one-year mortality.

The Dutch biotech's Phase I data show its nOMV platform induced mucosal and systemic immunity in healthy adults, published in peer-reviewed journal Vaccines.

The peer-reviewed Oxford study of 409 men over six years underpins the GPS-ProtecT randomised controlled trial of mdxhealth's 17-gene prostate assay.

The Riyadh-based digital mental health platform will embed psychological support services, joint research, and staff training across the Jeddah campus.

The pan-European research network intends to test whether brensocatib can modify bronchiectasis disease course over three years in six countries.

AC01, an oral ghrelin mimetic, showed haemodynamic gains and no serious adverse events in 58 HFrEF patients, supporting a Phase 2b trial.

Updated data from the 222-patient RCT showed XWRAP nearly doubled complete wound closure rates versus standard of care alone at 12 weeks.

Germany's BfArM has cleared Silexion's siRNA candidate SIL204 for a Phase 2/3 trial in locally advanced pancreatic cancer, with first dosing expected

Boehringer Ingelheim has initiated three Phase III trials covering obrixtamig in SCLC and epNEC, and zongertinib in resectable HER2-mutant NSCLC.

Thirty-five studies featuring optical genome mapping appeared at ESHG 2026, up from 21 the prior year, spanning authors across 17 countries.